NovoCure Reports 12% Revenue Growth to $174.1 Million in Q1 2026

NovoCure Limited reported its financial results for the first quarter of 2026, revealing net revenues of $174.1 million, a 12% increase from $155.0 million in the same period of 2025. The growth was primarily driven by a $16.3 million increase in international markets, particularly in Germany and France, alongside a $2.8 million rise in the U.S. market. The company’s gross profit for the quarter was $135.1 million, resulting in a gross margin of 78%, up from 75% in the prior year. However, NovoCure recorded a net loss of $71.1 million, compared to a loss of $34.3 million in the first quarter of 2025, reflecting increased operating expenses.

Operating expenses surged to $202.5 million, a 31% increase from $154.3 million in the previous year. This rise was largely attributed to a significant increase in general and administrative expenses, which jumped 92% to $85.9 million, primarily due to share-based compensation related to the FDA approval of Optune Pax. Research and development costs also rose by 8% to $58.3 million, driven by increased clinical trial activities. Sales and marketing expenses increased by 5% to $58.4 million, reflecting efforts related to the launches of Optune Pax and Optune Lua.

In terms of operational metrics, the number of active patients receiving treatment with NovoCure's products reached 4,791 by the end of March 2026, up from 4,268 a year earlier. The company reported 2,439 total active patients in the U.S., with notable growth in both Optune Gio and Optune Lua. The international markets also saw an increase in active patients, particularly in Germany and France, contributing to the overall revenue growth. The company continues to expand its market presence, with ongoing efforts to secure reimbursement policies for its products in various regions.

NovoCure's balance sheet as of March 31, 2026, showed total assets of $787.9 million, a decrease from $804.3 million at the end of 2025. The company had cash, cash equivalents, and short-term investments totaling $432.0 million, down from $447.7 million at the end of the previous year. The decrease was primarily due to cash used in operations. The company’s accumulated deficit increased to $1.36 billion, reflecting its ongoing investment in product development and market expansion.

Looking ahead, NovoCure remains focused on driving the commercial adoption of its products and expanding its clinical pipeline. The company is actively pursuing regulatory approvals for new indications and exploring opportunities to enhance its product offerings. Despite the challenges posed by rising operational costs and market conditions, NovoCure is committed to maintaining financial health and flexibility as it positions itself for future growth.